Rapastinel

NMDA Receptor Glycine-Site Partial Agonism#

Rapastinel is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH₂) that binds the glycine co-agonist site of the NMDA receptor as a positive allosteric modulator with partial-agonist properties. The pharmacology is self-limiting by design — it potentiates NMDAR currents when ambient glycine is low and dampens them at saturating glycine concentrations, giving the molecule a "smart" modulatory profile that avoids the open-channel blockade and dissociative liability of ketamine, memantine, or PCP.

"Rapastinel acts as a positive allosteric modulator of the glycine site of the NMDA receptor, facilitating synaptic plasticity without producing psychotomimetic effects." — Moskal JR et al., Current Neuropharmacology, 2017

Optimal NMDAR modulation occurs in the 1–10 µM range in [³H]MK-801 binding assays. The compact β-1 rigid conformation, stabilized by intramolecular hydrogen bonds, allows the tetrapeptide to cross the blood-brain barrier with a brain uptake index of 80 ± 15 by the Oldendorf method — unusually high for a peptide of this size, and the reason IV bolus translates into central activity within minutes.

Long-Term Potentiation and Metaplasticity#

The pharmacokinetic half-life is roughly 7–10 minutes, but the pharmacodynamic effect outlives plasma exposure by orders of magnitude. A single bolus shifts the hippocampus and medial prefrontal cortex into a sustained metaplastic state — Schaffer-collateral LTP is facilitated, mature dendritic spine density increases in dentate gyrus and layer-V mPFC at 24 h, and the effect is still measurable two weeks later.

"A single administration of rapastinel facilitated long-term potentiation and triggered metaplasticity changes in medial prefrontal cortex and hippocampus that lasted at least two weeks." — Burgdorf J et al., Neuroscience, 2015

This is the mechanistic basis for the weekly-to-biweekly dosing cadence used across the Phase 2 program. The molecule is not "in the system" in any meaningful PK sense between doses — the synaptic architecture it leaves behind is what is being dosed.

BDNF and mTORC1 Signalling Convergence#

Downstream of the NMDAR-glycine-site event, rapastinel activates the same intracellular plasticity cascade that ketamine triggers: BDNF release, TrkB activation, and mTORC1-driven dendritic protein synthesis. The functional outcome — rapid antidepressant action, anhedonia reversal, dendritic spine maturation — converges on the ketamine pathway, but the upstream entry point is different.

"Rapastinel produces rapid and sustained antidepressant effects with a mechanism converging on BDNF and mTORC1 signaling, but without the acute glutamate surge or psychotomimetic profile of ketamine." — Kato T, Duman RS, Pharmacology Biochemistry and Behavior, 2020

For users running rapastinel as a ketamine-adjacent plasticity stack, this is the practical point: the two compounds reach the same destination from different doors, which is why community protocols sometimes follow a ketamine session with a rapastinel bolus 4–7 days later to extend the plasticity window without re-loading dissociative exposure.

Pro-Cognitive Effect at Low Dose#

The cognitive readout is dose-separable from the antidepressant readout. At approximately 1 mg/kg IV, rapastinel maximally enhances trace eyeblink conditioning, alternating T-maze, and Morris water maze performance in both young and aged rodents — a dose substantially below the 5–10 mg/kg used for mood endpoints. This is the mechanistic anchor for the microdose cognitive protocol the nootropics community has converged on: 1 mg/kg IV every 5–7 days, timed to high cognitive workload.

The effect tracks LTP facilitation rather than acute receptor occupancy — there is no "feel" comparable to a stimulant or a dissociative, and users expecting one report disappointment. What shows up instead is a gradual lift in learning efficiency and mood floor over the hours and days following the bolus.

Dissociation-Free Profile#

Unlike ketamine, rapastinel does not produce psychotomimetic or dissociative effects in clinical or preclinical work, even at doses well above the antidepressant range. This is the consequence of the glycine-site mechanism — modulation rather than open-channel blockade — and it held up across more than 1,500 subjects in the Phase 1–3 program.

"Both rapastinel and R-ketamine produced rapid antidepressant-like effects in the model, but rapastinel did so without inducing dissociative or psychotomimetic symptoms." — Yang B et al., Psychopharmacology, 2016

The Allergan Phase 3 program ultimately failed, but the consensus mechanistic interpretation is not that the pharmacology was wrong — it is that the fixed 225 mg / 450 mg flat dose abandoned the weight-normalized 5–10 mg/kg ranging that produced the Phase 2 signal. The community has correspondingly anchored protocols back to mg/kg dosing.

"Phase 3 trials of rapastinel using fixed 225 mg and 450 mg IV doses failed to meet primary clinical endpoints, highlighting the importance of weight-based dosing established in earlier studies." — Johnston JN et al., Neuropharmacology, 2023

Common (most users)#

Across the Phase 1–3 program (>1,500 subjects), rapastinel's acute side-effect profile was notably mild and transient — the defining feature being the absence of psychotomimetic or dissociative effects that characterize ketamine and esketamine.

• Mild dizziness — typically resolves within 15–30 minutes of the IV bolus. Subjects remain supine for 10 minutes post-infusion as a precaution.
• Transient headache — most common in the first hour post-dose. Hydration before infusion mitigates incidence; standard analgesics are compatible.
• Mild nausea — usually peri-infusion. A slower bolus rate (over 1–2 min rather than rapid push) reduces incidence. Light food 30–60 min prior is the community workaround.
• Brief sedation / drowsiness — reported in a minority. Dosing in the evening rather than mid-day sidesteps the productivity hit.
• Paresthesia at or near the infusion site — short-lived, resolves spontaneously. Larger-bore catheter and proper saline flush minimize incidence.

"Rapastinel acts as a positive allosteric modulator of the glycine site of the NMDA receptor, facilitating synaptic plasticity without producing psychotomimetic effects." — Moskal et al., Current Neuropharmacology (2017)

Uncommon (dose-dependent or individual)#

These cluster at the high end of the dose range (10 mg/kg and above in the Phase 2 record) and in subjects with higher baseline anxiety or autonomic reactivity.

• Inverted-U efficacy at 30 mg/kg — the Phase 2 proof-of-concept signal flattened at 30 mg/kg IV without added benefit. If a 5–10 mg/kg protocol delivers the desired readout, escalation past that range is wasted material and adds side-effect burden without efficacy upside.
• Transient anxiety or autonomic activation — a small subset of subjects report a brief sympathetic-tone spike in the first 30 minutes. Backing off to 1–3 mg/kg resolves it.
• Insomnia after late-day dosing — the cognitive-activation profile can interfere with sleep onset if the bolus is administered within ~6 hours of bedtime. Morning or early-afternoon dosing is the protocol-level fix.
• Mood lability in the days following the bolus — uncommon but documented in community reports, particularly in stacks combining rapastinel with other plasticity-active agents (ketamine, psychedelics). Spacing modalities by ≥5–7 days resolves the overlap.
• No clinically meaningful changes in CBC, LFTs, renal panel, or cardiac parameters were reported in the published trial record. Standard cycle bloodwork (lipids, LFTs, CBC, hormonal panel) for users running rapastinel alongside AAS is sufficient — no rapastinel-specific monitoring is indicated.

Rare but serious#

The clinical record is remarkably clean — no serious cardiac, hepatic, hematologic, urogenital, or abuse-potential signals emerged across the Phase 1–3 program. The items below are theoretical or mechanism-derived rather than well-documented.

• Seizure activation — NMDAR-facilitating compounds carry a theoretical proconvulsant signal. The published rapastinel record does not show this, but subjects with a personal or strong family history of seizure disorder should treat the high end of the dose range with caution and discontinue at any prodromal sign (aura, focal twitching, altered consciousness).
• Emergent psychotic symptoms — not observed in trials, but NMDAR modulation in subjects with latent psychosis is uncharacterized. Auditory hallucinations, paranoid ideation, or thought disorganization warrant immediate discontinuation.
• Endotoxin / sterility events — the dominant real-world risk for research-chemical rapastinel is not the molecule but the supply chain. Fever, rigors, or systemic inflammatory response within hours of an IV bolus is a pyrogen reaction, not a pharmacology problem. Source vetting, proper reconstitution with bacteriostatic water, sterile filtration, and discarding reconstituted vials past 14 days are the controls.
• Hypersensitivity reaction — peptide hypersensitivity is rare but possible with any injectable peptide. Urticaria, bronchospasm, or facial angioedema is a hard stop.

"Both rapastinel and R-ketamine produced rapid antidepressant-like effects in the model, but rapastinel did so without inducing dissociative or psychotomimetic symptoms." — Yang et al., Psychopharmacology (2016)

Hard contraindications#

• Active psychosis or schizophrenia — NMDAR modulation in psychotic illness is not characterized for this molecule. Do not use.
• Seizure disorder — theoretical proconvulsant liability via NMDAR facilitation. Do not use.
• Pregnancy and lactation — no human reproductive safety data. Do not use.
• Concurrent dissociatives — ketamine, esketamine, memantine, dextromethorphan, PCP-class agents. Mechanistic overlap with unknown additive plasticity effects; not studied in combination. If a ketamine session is part of the protocol, separate modalities by ≥5–7 days.
• Peptide hypersensitivity — known allergic reaction to rapastinel or structurally related glycine-site peptide modulators.
• Non-IV routes are not validated — oral, sublingual, and buccal routes are non-viable (the tetrapeptide is digested). SC and intranasal routes lack PK validation; community reports are inconsistent and effects are weak-to-absent compared to IV. Substituting routes is not a workaround, it is a different (and uncharacterized) protocol.

Gender, hormonal, and PCT considerations#

Rapastinel is non-hormonal. It does not interact with the HPG, HPA, or HPT axes. There is no virilization risk, no estrogenic or androgenic activity, no suppression to recover from, and no PCT relevance. Weight-based dosing (mg/kg) applies uniformly across the subject pool — no gender adjustment is indicated in the clinical record. The Phase 3 program's switch to fixed flat dosing (225 mg / 450 mg) is widely viewed as a contributor to its failure, and the community has correctly converged back on the weight-normalized 1–10 mg/kg protocol from Phase 2.

"Phase 3 trials of rapastinel using fixed 225 mg and 450 mg IV doses failed to meet primary clinical endpoints, highlighting the importance of weight-based dosing established in earlier studies." — Johnston et al., Neuropharmacology (2023)